Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 Tolerability, Safety, and PK in Healthy Adults
NCT06935266Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- SC (Subcutaneous administration)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TAK-881 in primary immunodeficiency (PI) (8 cohorts), sponsored by Takeda. Primary endpoints: Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment at Day 57 and Number of Tolerable Infusions by TAK-881 Treatment at Day 57. Started Apr 2025; status: completed.
02
Drugs
TAK-881
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT06935266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935266.